A Single-site, Open-label, Fixed-sequence Phase 1 Study Evaluating the Effect of Eliglustat (Genz-112638) on the Pharmacokinetics and Safety and Tolerability of Digoxin in Healthy Adult Subjects.

Trial Profile

A Single-site, Open-label, Fixed-sequence Phase 1 Study Evaluating the Effect of Eliglustat (Genz-112638) on the Pharmacokinetics and Safety and Tolerability of Digoxin in Healthy Adult Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2013

At a glance

  • Drugs Digoxin (Primary) ; Eliglustat (Primary)
  • Indications Arrhythmias; Lysosomal storage diseases
  • Focus Pharmacokinetics
  • Sponsors Genzyme Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Apr 2012 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
    • 06 Apr 2012 Actual initiation date changed from May 2011 to Aug 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top